Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
Allergy. 2022 Aug;77(8):2468-2481. doi: 10.1111/all.15372. Epub 2022 Jun 2.
T-cell lymphopenia and functional impairment is a hallmark of severe acute coronavirus disease 2019 (COVID-19). How T-cell numbers and function evolve at later timepoints after clinical recovery remains poorly investigated.
We prospectively enrolled and longitudinally sampled 173 individuals with asymptomatic to critical COVID-19 and analyzed phenotypic and functional characteristics of T cells using flow cytometry, 40-parameter mass cytometry, targeted proteomics, and functional assays.
The extensive T-cell lymphopenia observed particularly in patients with severe COVID-19 during acute infection had recovered 6 months after infection, which was accompanied by a normalization of functional T-cell responses to common viral antigens. We detected persisting CD4 and CD8 T-cell activation up to 12 months after infection, in patients with mild and severe COVID-19, as measured by increased HLA-DR and CD38 expression on these cells. Persistent T-cell activation after COVID-19 was independent of administration of a COVID-19 vaccine post-infection. Furthermore, we identified a subgroup of patients with severe COVID-19 that presented with persistently low CD8 T-cell counts at follow-up and exhibited a distinct phenotype during acute infection consisting of a dysfunctional T-cell response and signs of excessive pro-inflammatory cytokine production.
Our study suggests that T-cell numbers and function recover in most patients after COVID-19. However, we find evidence of persistent T-cell activation up to 12 months after infection and describe a subgroup of severe COVID-19 patients with persistently low CD8 T-cell counts exhibiting a dysregulated immune response during acute infection.
T 细胞减少和功能障碍是严重急性冠状病毒病 2019(COVID-19)的标志。临床康复后 T 细胞数量和功能如何演变仍知之甚少。
我们前瞻性招募了 173 名无症状至重症 COVID-19 患者,并进行了纵向采样,使用流式细胞术、40 参数质谱流式细胞术、靶向蛋白质组学和功能测定分析 T 细胞的表型和功能特征。
在急性感染期间,特别是在重症 COVID-19 患者中观察到的广泛 T 细胞减少在感染后 6 个月内已恢复,同时 T 细胞对常见病毒抗原的功能反应也恢复正常。我们检测到,在感染后 12 个月内,轻度和重度 COVID-19 患者仍存在 CD4 和 CD8 T 细胞持续激活,这些细胞上 HLA-DR 和 CD38 的表达增加。COVID-19 后持续的 T 细胞激活与感染后 COVID-19 疫苗的接种无关。此外,我们在一组严重 COVID-19 患者中发现,这些患者在随访时 CD8 T 细胞计数持续较低,并在急性感染期间表现出独特的表型,包括 T 细胞功能障碍和过度产生促炎细胞因子的迹象。
我们的研究表明,COVID-19 后大多数患者的 T 细胞数量和功能恢复。然而,我们发现感染后长达 12 个月存在持续的 T 细胞激活,并描述了一组严重 COVID-19 患者,其 CD8 T 细胞计数持续较低,在急性感染期间表现出失调的免疫反应。